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Abstract. Tumor-associated macrophages (TAMs) are major 
constituents of the tumor microenvironment in solid tumors 
and have been implicated as mediators of tumor progression, 
invasion and metastasis. Correspondingly, accumulation of 
TAMs is associated with unfavorable clinical outcomes in 
numerous types of solid tumors. E-selectin is a hallmark of 
inflammation and a key adhesion molecule that accommodates 
the initial contact of circulating immune cells with the inflamed 
vessel surface. Currently, the association between E-selectin 
and TAMs is not fully elucidated; therefore, the present study 
investigated the association between vessel inflammation, 
TAM infiltration, and clinical outcome in breast cancer. A 
total of 53 procedure-naïve invasive breast cancer cases were 
immunohistochemically analyzed for the presence of cluster of 
differentiation (CD)68+ TAMs, E-selectin+ vessels and tumor 
inflammation. The association between CD68 and E‑selectin 
expression, and tumor inflammation as well as overall survival 
was evaluated using Kaplan-Meier survival curves and multi-
variable Cox's proportional hazards regression analysis. The 
abundance of TAMs was identified to be positively associated 
with tumor inflammation, estrogen receptor and E‑selectin 
expression levels. A greater prevalence of TAMs and tumor 
inflammation was significantly associated with shorter overall 
survival times. E‑selectin expression levels were significantly 
higher in tumor vessels among elderly patients, but were not 
associated with overall survival. The abundance of TAMs 
was associated with the presence of E-selectin-expressing 
inflamed tumor vessels and tumor inflammation, as well as 
overall survival in patients with invasive breast carcinoma.
Introduction
Inflammation is a hallmark of cancer, not only triggering 
tumor development, but also promoting tumor progression, 
therapy resistance and metastasis (1,2). Breast cancer is a 
common type of malignancy, with >1.67 million new cases 
and 522,000 mortalities reported in 2012 worldwide (3). 
Approximately 30% of females with breast cancer experience 
recurrence within 5 years, with a 50% chance of developing 
distant metastases (4,5). Cancer is aptly described as a wound 
that never heals since solid tumors are chronically inflamed 
and immune cells in concert with other stromal components 
influence cancer cell behavior. Immune infiltrates represent a 
significant component of the mass in solid tumors (6) and aid 
in regulating cancer cell growth, angiogenesis and invasion 
via the production of an array of cytokines, reactive oxygen 
species, and proteases (7-10). Tumor-associated macrophages 
(TAMs) are a prominent component, serving a central role in 
promoting tumor growth and metastasis (1). Accordingly, a 
greater abundance of TAMs has been associated with metas-
tasis and poor prognosis in numerous types of solid tumors 
including breast (11,12), lung (13,14), prostate (15), colorectal, 
and pancreatic cancer (16-19). TAMs are recognized as 
potent producers of growth factors (transforming growth 
factor-β, fibrobast growth factors and epidermal growth 
factor), pro-angiogenic factors [vascular endothelial growth 
factor, tumor necrosis factor-α (TNF-α), interleukin (IL)-8, 
matrix metalloproteinase and platelet derived growth factor], 
proteases (cathepsin and serine proteases) and cytokines 
(IL-10), which profoundly affect epithelial cancer cell growth, 
angiogenesis, local invasion, extracellualr matrix degrada-
tion, epithelial-mesenchymal transition, metastasis, therapy 
response, and immunosuppression (20-22).
Macrophages originate from peripheral blood mono-
nuclear cells derived from bone marrow and are recruited into 
the tumor via colony stimulating factor 1 and C-X-C motif 
chemokine ligand 12, released from cancer cells or the tumor 
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microenvironment (23). For successful tissue migration, circu-
lating immune cells undergo a sequential multistep adhesion 
cascade initiated by adhesion to the vessel surface (24-28). 
Vascular expression of selectin family member proteins aids 
physical interaction with counter-receptor ligands expressed 
on immune cells, including sialyl Lewisx (sLex), sialyl 
LewisA (sLeA), cluster of differentiation (CD)44, cutaneous 
lymphocyte-associated antigen and P-selectin glycoprotein 
ligand-1 (29-31). E-selectin (also known as CD62E, endothe-
lial cell leukocyte adhesion-1 or Leukocyte-endothelial cell 
adhesion molecule 2) is exclusively expressed on the luminal 
surface of inflamed vessels and serves a role in the catch bond 
that switches from rolling adhesion to integrin‑mediated firm 
adhesion (32). Thus, elevated vascular E-selectin expression 
levels have been reported in a range of solid tumors, including 
breast (11,12), lung (13,14) and pancreatic (16,18) cancer. 
E-selectin expression often synchronizes with an abundance of 
sLex- or sLeA‑positive immune infiltrates in the tumor (33,34). 
The present study investigated the abundance of tumor 
vascular E-selectin and macrophage marker CD68 expression 
levels in order to understand the association between inflamed 
tumor vessels and TAM infiltration, as well as their role in 
breast cancer prognosis.
Materials and methods
Tumors. Surgical whole mounts from a total of 100 human 
breast carcinoma specimens from females diagnosed between 
January 1987 and December 1988 from the pathology archives 
at Thomas Jefferson University (Philadelphia, USA) were used 
in the present study. The average age of patients at the time 
of surgery was 61.8±16.4 years. Cases with tissue containing 
ductal carcinoma in situ (DCIS) only, inflammatory breast 
cancer or other concurrent malignancies were excluded from 
the present study. Cases with no reactivity to vimentin staining 
were eliminated from the study. Only cases with fully anno-
tated information regarding demographics, estrogen receptor 
(ER) expression, histology grade and overall survival (OS) 
were used in final analyses.
Immunohistochemistry. For quality control, cases were first 
immunohistochemically stained with anti-vimentin mono-
clonal antibody (cat. no. 550513; BD Biosciences, San Jose, 
CA, USA) at a 1:250 dilution overnight at 4˚C. Those without 
vimentin reactivity were removed from the study. Double 
immunohistochemistry was performed using formalin‑fixed 
paraffin‑embedded tumor sections (4 µm thickness). Briefly, 
following deparaffinization and rehydration, antigen retrieval 
was performed using Envision Flex Target Retrieval Solution 
(pH 6.1; Dako; Santa Clara, CA, USA) in a pressure cooker 
for 20 min at 102˚C. Endogenous peroxidase and nonspecific 
epitopes were blocked with 0.3% hydrogen peroxide in abso-
lute methanol for 30 min at room temperature and 5% normal 
horse serum and 1% normal goat serum (Sigma-Aldrich; 
St. Louis, MO, USA) for 1 h at room temperature. Sections 
were incubated with mouse anti-E-selectin monoclonal 
antibody at 1:100 (cat. no. MO20039; Neuromics, Inc., 
Minneapolis, MN, USA) overnight at room temperature. 
Following washing with PBS and subsequent blocking with 
5% normal horse serum and 1% normal goat serum for 5 min 
at room temperature, the slides were incubated with pre-dilute 
secondary horseradish peroxidase (HRP)-polymer conjugated 
anti-mouse IgG (cat. no. K4001; Dako) for 30 min at room 
temperature. HRP was detected using 3-3'-diaminobenzidine 
(DAB; Biocare Medical LLC, Paheco, CA, USA) substrate for 
10 min at room temperature and enhanced using DAB Sparkle 
(Biocare Medical LLC) for 1 min at room temperature. 
Residual antibodies were eluted using Denaturing solution 
(Biocare Medical LLC) at a 1:3 dilution for 3 min at room 
temperature to ensure no cross reaction between the first and 
second staining. Slides were blocked with 5% normal horse 
serum and 1% normal goat serum for 5 min at room tempera-
ture and then incubated with mouse anti-CD68 monoclonal 
antibody at 1:25 (cat. no. M0876; Dako) overnight at 4˚C. 
Following a brief wash with PBS, the slides were incubated 
with pre-dilute secondary alkaline phosphatase-polymer 
conjugated MACH2 anti-mouse IgG (cat. no. MALP521; 
Biocare Medical LLC) for 1 h at room temperature and then 
visualized using Fast-Red (Biocare Medical LLC) for 7 min, 
followed by counterstain with Mayer Hematoxylin (Dako) for 
4 min both at room temperature. The slides were air-dried and 
mounted. As a negative control, breast carcinoma tissues were 
immunostained with the secondary IgG only.
Pathologic evaluation. All immunohistochemically stained 
slides were evaluated by a board certified surgical pathologist 
(Department of Pathology, School of Medicine, University of 
Oklahoma Health Sciences Center, Oklahoma City, OK, USA) 
for breast pathology. The tumors were classified and graded 
according to the protocol from of the College of American 
Pathologists (Protocol for the Examination of Specimens from 
Patients with Invasive Carcinoma of the Breast according to 
InvasiveBreast 3.3.0.0.) (35). Tumor inflammation was defined 
as positive or negative, as characterized by the presence 
of lymphocyte clusters. Immunohistochemical reaction to 
E-selectin was graded using intensity as a score of 0, 1+, 2+ or 
3+ for no, weak, moderate or strong reaction in endothelial cells 
within the tumor, respectively. Immunohistochemical staining 
of CD68 was quantitatively categorized as a score of 0, 1+, 2+ 
or 3+ for no CD68+ cells, ≤10 CD68+ cells, 11-20 CD68+ cells 
or ≥21 CD68+ cells in the observing field at x200 magnifica-
tion within the tumor, respectively. All images were viewed 
under a light microscope (DM2500; Leica, Buffalo Grove, IL, 
USA) and images were captured using digital cooling color 
camera (DFC450; Leica).
Statistical analysis. The Fisher's exact test was used to analyze 
the association between age and tumor pathological parameters 
using CD68 and E-selectin expression levels. Spearman's rho 
was used to determine the correlation between CD68+ TAMs, 
and E‑selectin expression level and tumor inflammation. The 
Kaplan-Meier method was used to estimate OS as a function 
of time, and differences were analyzed using the log-rank 
test. Cox proportional hazards regression analysis was used 
for multivariable analysis of prognostic factors in relation to 
OS. The statistical software SAS, version 9.4 (SAS Institute 
Inc., Cary, NC, USA) was used to perform statistical analyses. 
GraphPad Prism version 6 (Graphpad Software, Inc., La Jolla, 
CA, USA) was used to generate Kaplan-Meier curves. P<0.05 
was considered to indicate a statistically significant difference.
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Results
Tumor characteristics. Following exclusions, a total of 53 inva-
sive breast cancer cases that had been first‑time diagnosed by 
surgical resection in 1986-1988 at Thomas Jefferson University 
were used in the present study. Tumor characteristics of these 
patients are presented in Table I. Cases were categorized as 
either high (score 3+) or low (score 0-2+) CD68 expression 
level according to the abundance of CD68+ TAMs in the tumor 
core and high (score 3+), or low (score 0-2+) expression level 
of E-selectin on vessels in the tumor area. CD68+ TAMs were 
significantly associated with tumor inflammation (P=0.005) 
and ER status (P=0.037). E‑selectin expression level was asso-
ciated with age (P=0.016) and was significantly higher among 
females over the age of 60 years (Table I).
Pattern of CD68+ TAM infiltration and E‑selectin+ vessel 
inf lammation in breast tumors. Representative images 
of high and low expression levels of CD68+ TAMs, and 
E-selectin+ inflamed vessels are presented in Fig. 1. Various 
expression levels of CD68+ TAMs were consistently present 
in the tumor stroma and core of all 53 cases (Fig. 1A-C). 
Considerable, multilayered CD68+ TAM deposition in 
the necrotic area of the tumors was observed. CD68+ 
TAMs were also abundant in the mammary fat adjacent 
to the tumor, as well as around the luminal surface of 
vessels (Fig. 1C). E-selectin was predominantly expressed 
on vessels within the tumor stroma (Fig. 1D and E). No 
positive signal for E-selectin was detected in other tumor 
components, including cancer cells, fibroblasts, immune 
infiltrates or the apical side of the vessels. The size of 
E-selectin-expressing vessels varied from small capillaries 
to large vessels in the stroma and fat adjacent to the invasive 
front of tumors. Vessel structure was well retained within 
the stroma but often compressed, crushed or even absent 
in the tumor core. Overall, 88.7% of the breast carcinoma 
cases exhibited E-selectin expression on their tumor 
vessels. Consistent with inflammation of the adipose tissue 
adjacent to the tumor, E-selectin expression level was also 
high in vessels of the neighboring peripheral adipose tissue. 
Of note, vascular E-selectin expression level was present 
in the stroma surrounding the mammary duct in invasive 
carcinomas that retained a ductal structure (Fig. 1F). A 
similar pattern of E-selectin expressing vessels in the 
stroma around the mammary duct in DCIS only cases was 
also revealed (data not shown), suggesting the presence of 
peritumoral inflammation at the pre‑invasive stage.
Association between vessel inflammation and TAM infiltra‑
tion. Double immunohistochemistry for CD68 (pink) and 
E-selectin (brown) was performed to evaluate their asso-
ciation. CD68+ TAMs were abundant in close proximity to 
E-selectin-expressing vessels in the tumor stroma and periph-
eral tissue adjacent to the tumor (Fig. 2A and B). CD68+ TAMs 
were sparsely present in carcinoma cell rich areas; however, 
E‑selectin expression was limited to the surrounding inflamed 
area and absent or weakly present in the tumor core (Fig. 2B). 
CD68+ TAMs were also highly abundant in necrotic areas, but 
E-selectin was absent within and adjacent to the necrotic core 
(Fig. 2C). TAMs and E-selectin were present at the location 
where the ductal structure was retained (Fig. 2D). Association 
between the abundance of CD68+ TAMs and E-selectin+ 
vessels was evaluated using a 4-level scoring scale (0, 1+, 2+, 
3+) for the expression level of each marker. High abundance 
of CD68+ TAMs and E-selectin+ vessels (3+/3+) was demon-
strated in 7.5% of the overall analyzed samples. CD68+ TAMs 
and E-selectin expression levels were positively correlated 
(r=0.30, P=0.030; Table II). Additionally, CD68+ TAMs were 
Table I. Association between clinicopathologic parameters, and CD68 and E-selectin expression in procedure-naïve invasive 
breast carcinoma tissues.
 CD68 expression E-selectin expression
Clinicopathologic  Total no.  -------------------------------------------------------------- --------------------------------------------------------------
parameters cases Low High P-value Low High P-value
All cases 53 34 19  41 12 
Age    0.349   0.016a
  ≤60 20 14 6  19 1 
  >60 33 20 13  22 11 
Tumor inflammation    0.005a   0.540
  (-) 25 21 4  19 6 
  (+) 28 13 15  22 6 
Nottingham histological grade    0.561   0.455
  Grade I 3 8 4  3 0 
  Grade II + III 50 26 15  38 12 
ER status    0.037a   0.521
  Negative 11 4 7  9 2 
  Positive 42 30 12  32 10 
aStatistically significant difference following Fisher's exact probability test. CD68, cluster of differentiation 68.
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significantly correlated with tumor inflammation (r=0.54, 
P=0.001; Table II).
Abundance of markers and clinical outcome. OS was deter-
mined and graphically presented using the Kaplan-Meier 
method, and a Cox proportional hazards regression model 
was used for multivariable analysis of the association between 
clinicopathological parameters and marker expression level 
with OS. Tumor inflammation was significantly associated 
with OS among patients with breast cancer [hazard ratio 
Figure 2. Double immunohistochemistry of TAM and E-selectin. (A and B) Spatial association of CD68+ TAM and E-selectin in the tumor stroma of invasive 
breast carcinoma tissues. (C) Absence of E-selectin expressing vessels in necrotic area. (D) Presence of CD68+ TAM and E-selectin in stroma of non-carcinoma 
area of invasive carcinoma tissue. Brown indicates E‑selectin and red indicates TAM. The images are representative at a final magnification of x200. Scale bar 
indicates 100 µm. V, vessels; C, cancer cells; N, necrotic area; CD68, cluster of differentiation 68.
Figure 1. TAM and E-selectin expression levels in breast tumor tissues. (A-C) Single immunohistochemical staining of CD68+ TAMs for analysis of the distri-
bution at various areas of the invasive breast carcinoma tissues (red). (D-F) Differential E-selectin expression in vessel surface in breast carcinomas (brown). 
The images are representative at a final magnification of x200. Scale bar indicates 100 µm. V, vessels; A, adipocytes; CD68, cluster of differentiation 68.
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(HR), 2.00; confidence interval (CI) 95%, 1.03‑4.06; P=0.044; 
Fig. 3A]. However, inflammation in the tumor periphery lacked 
association with OS (HR, 1.20; CI 95%, 0.560‑2.61; P=0.629; 
data not shown). Compared with tissue samples with lower 
expression levels of CD68+ TAMs, higher expression levels of 
CD68+ TAMs in the tumor core were significantly associated 
with shorter OS at the 10-year follow-up (HR, 2.23; CI 95%, 
1.12‑5.54; P=0.017; Fig. 3B). Conversely, CD68+ TAMs in the 
tumor periphery were not significantly associated with OS (HR, 
1.39; CI 95%, 0.59‑3.50; P=0.420; data not shown). Although 
the abundance of E-selectin+ vessels and CD68+ TAMs were 
positively correlated, E-selectin expression level alone did not 
impact OS at the tumor (HR, 0.71; CI 95%, 0.32‑1.57; P=0.395; 
Fig. 3C) or periphery. Kaplan-Meier analysis demonstrated 
that OS was unaffected by age for CD68, E-selectin or tumor 
inflammation statuses (data not shown). Finally, multivariable 
analysis of procedure-naïve breast tumor tissues revealed that 
the presence of abundant CD68+ TAMs was an independent 
predictor of OS (HR, 2.37; 95% CI, 1.02‑5.36; P=0.045) 
following adjustment for ER status, tumor inflammation and 
E-selectin expression level (Table III).
Discussion
Tissue infiltration by circulating leukocytes occurs in response 
to tissue damage and injury. In the context of solid tumors, cell 
death arises from intrinsic and extrinsic inducers, initiating an 
inflammatory cascade in an attempt to scavenge debris, and 
repair damaged tissue. Intrinsic cell death is hypoxia-derived 
necrosis or DNA-damage-associated apoptosis, whereas 
extrinsic cell death is associated with external stimuli, including 
chemotherapy, biopsy, surgery or radiation therapy. The stan-
dard of care for breast cancer has altered significantly over the 
past 3 decades (35). Diagnostic needle biopsy became popular 
in the 1990s (36) and neoadjuvant chemotherapy for relatively 
large, locally advanced tumors emerged in the 2000s (37). 
Both procedures provoke inflammation accompanied by cell 
death in the tumor and neighboring peripheral tissue. Thus, it is 
likely that recent surgically resected tumors contain inflamma-
tion induced by extrinsic stress along with naturally occurring 
intrinsic cell death. Although external stress naïve tumors can 
be analyzed using biopsy samples, such samples contain only 
small and limited amounts of tissue, making the capture of the 
overall tumor environment difficult. Analysis of naïve tumors 
collected by excisional biopsy essentially eliminates locally 
advanced tumors since this method is typically only used in 
early stage small-sized tumors. Thus, in order to understand 
the association of vessel inflammation and TAM infiltration 
in intrinsic tumor inflammation, the present study specifically 
targeted surgically resected, procedure-naïve breast tumor 
tissue samples collected between 1986 and 1988, when needle 
biopsy was not yet broadly adopted as the standard of care.
The involvement of E-selectin in cancer has long been 
recognized, as evidenced by histopathological studies; 
however, its clinical implications have been controver-
sial (11,12,38). The results of the present study revealed that 
88.7% of procedure-naïve breast tumors expressed E-selectin 
in the vessels within the tumor. Previously, the prevalence 
of E-selectin-positive vessels has been reported as 55.7% 
(n=113) (11) and 77.6% (n=22) (12) in frozen breast tumor tissue 
sections. A previous study by Charpin et al (11) demonstrated 
a positive association between E-selectin expression level, 
and vascular cell adhesion molecule-1, very late antigen-2 
and CD44 expression levels, and a negative association with 
E-cadherin expression level. However, the latter was postiviely 
associated with ER-negative breast cancer, which may be due 
to the release of higher expression levels of IL-1 and TNF-α 
from ER-negative compared with ER-positive breast cancer 
cells. The present study and the study by Charpin et al (11) 
did not determine an association between E-selectin expres-
sion and ER status, but both studies identified an association 
between E-selectin, and CD68+ TAMs or CD44+ immune 
infiltrates, a common marker for immune cells.
TAMs are classified as either pro‑inflammatory M1 or 
pro-tumorigenic M2 macrophages (36), although it is yet to 
be determined which of these is more clinically important 
for prognosis (37,39). Unlike T-lymphocytes, whose pheno-
types are classified by differentiation, the TAM phenotype 
is plastic and determined by its surrounding microenviron-
ment (40). For example, the M1 phenotype can switch to M2 
in response to T helper 2-released cytokines, including IL-13 
and IL-4 (41). Accordingly, the overall composition and 
Table II. Association between CD68+ TAMs, and E-selectin 
expressing vessels and tumor inflammation in procedure‑naïve 
invasive breast carcinoma tissues.
 E‑selectin Inflammation
 ----------------------------------------------------------------------- -------------------------
CD68 0 1+ 2+ 3+ - +
0 0 0 0 0 0   0
1+ 3 5 4 2 13   1
2+ 1 6 10 3 8 12
3+ 2 2 8 7 4 15
 *P=0.030,  *P<0.001,
 r=0.302 r=0.541
E-selectin: 0, no immunohistochemical reaction; 1+, weakly; 2+, 
moderately; 3+, strong reactions in endothelial cells. CD68: 0, no CD68+ 
cells; 1+, ≤10 CD68+ cells; 2+, 11-20 CD68+ cells; 3+ ≥21 CD68+ cells. 
CD68, cluster of differentiation 68; TAMs, tumor-associated macro-
phages.
Table III. Multivariable Cox proportional hazard regression 
analysis of overall survival.
  Hazard
Variables P-value ratio 95% CI
Tumor inflammation 0.326 1.48 0.68-3.26
(ref. positive)
ER status (ref. negative) 0.341 1.50 0.65-3.42
E-selectin expression (ref. high) 0.112 0.46 0.18-1.20
CD68 expression (ref. high) 0.045a 2.34 1.02-5.36
aStatistically significant. CI, confidence interval; ER, estrogen receptor; 
CD68, cluster of differentiation.
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balance of immune subsets determines the pro-tumorigenic 
potential and fate of the tumor. TAMs were present in all 
procedure-naïve invasive breast carcinoma samples in the 
present study and their spatial distribution pattern, as well as 
abundance, differed among cases. TAMs were a predominant 
component near the necrotic core, in adipose tissue adjacent 
to the tumor and in the tumor stroma. Further investigation of 
TAM accumulation and phenotypic distribution at different 
locations may improve the understanding of their clinical 
implications.
E-selectin turnover is short, and it is shed into the 
circulation as a circulating form of E-selectin, soluble 
(s)E-selectin (42). sE-selectin has been used as a surrogate 
marker for vessel inflammation since sE‑selectin expression 
levels appear to be associated with the vascular E-selectin 
present on the surface of the endothelial cells (43-48). For 
example, the sE‑selectin expression level was significantly 
higher among patients with metastatic breast cancer compared 
with that of healthy counterparts (33.5 vs. 21.8 ng/ml; P<0.01), 
as well as in patients with liver metastasis compared with 
those without (55.3 vs. 26.0 ng/ml; P<0.0001). Thus, increased 
expression levels of sE-selectin were associated with reduced 
overall survival in breast cancer (49). Similarly, pre-surgical 
sE-selectin expression levels were higher in patients with 
colorectal cancer (43 ng/ml) compared with patients with 
benign diseases (43 ng vs. 31 ng/ml) and were positively 
associated with carcinoembryonic antigen tumor marker 
and poorer prognosis (both P<0.001) (50). However, a study 
of microarray data from 1,809 breast cancer patients with no 
previous treatment history revealed that E-selectin expression 
level was associated with longer survival times (HR, 0.67; CI 
95%, 0.54‑0.83; P=0.001)  (51). In the present study, E-selectin 
expression level in breast tumor tissue samples was more 
abundant in females >60 years compared with those ≤60. 
Elevated E-selection expression level among elderly females 
may be attributed to age-associated inflammation due to 
comorbidities, since sE-selectin expression levels are reported 
to be high in chronic inflammatory conditions, including 
arthritis (52,53), diabetes (52), atherosclerosis (54) and alco-
holism (55). However, E-selectin expression level in the tumor 
was not associated with OS following age adjustment in the 
present study (data not shown). The survival implications of 
E‑selectin expression may require integration of area‑specific 
expression (tumor or necrosis vs. stroma), type of survival 
(overall vs. disease specific) and comorbidity status. In conclu-
sion, tumor inflammation and E-selectin expression levels 
were identified to be positively correlated with TAMs, and the 
abundance of TAMs present in the tumor was an independent 
prognostic factor in invasive breast tumors.
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Figure 3. Overall survival by prevalence of (A) tumor inflammation, (B) TAM and (C) E‑selectin. Kaplan‑Meier survival curves according to tumor inflamma-
tion,  CD68+ TAMs and E-selectin+ vessels in 53 invasive patients with breast cancer. TAM, tumor-associated macrophage; CD68, cluster of differentiation 68.
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